Androgen receptor overexpression in prostate cancer in type 2 diabetes
Conclusions We report elevated androgen receptor signaling and activity presumably due to altered insulin/IGF-1 receptors and decreased levels of protective estrogen receptor ligands in prostate cancer in men with diabetes. Our results reveal new insights why these patients have a worse prognosis. These findings provide the basis for future clinical trials to investigate treatment response in patients with prostate cancer and diabetes.
Source: Molecular Metabolism - Category: Endocrinology Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Diabetes | Diabetes Type 2 | Endocrinology | Genetics | Insulin | Pathology | Prostate Cancer